» Articles » PMID: 8570644

Involvement of Ras/Raf/AP-1 in BMP-4 Signaling During Xenopus Embryonic Development

Overview
Specialty Science
Date 1996 Jan 23
PMID 8570644
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, we elucidated the role of bone morphogenetic protein 4 (BMP-4) in the dorsal-ventral patterning of the Xenopus embryo by using a dominant negative mutant of the BMP-4 receptor (DN-BR). The present paper describes the involvement of Ras, Raf, and activator protein 1 (AP-1) in BMP-4 signaling during Xenopus embryonic development. The AP-1 activity was determined by injecting an AP-1-dependent luciferase reporter gene into two-cell-stage Xenopus embryos and measuring the luciferase activity at various developmental stages. We found that injection of BMP-4 mRNA increased AP-1 activity, whereas injection of DN-BR mRNA inhibited AP-1 activity. Similar inhibitory effects were seen with injection of mRNAs encoding dominant negative mutants of c-Ha-Ras, c-Raf, or c-Jun. These results suggest that the endogenous AP-1 activity is regulated by BMP-4/Ras/Raf/Jun signals. We next investigated the effects of Ras/Raf/AP-1 signals on the biological functions of BMP-4. DN-BR-induced dorsalization of the embryo, revealed by the formation of a secondary body axis or dorsalization of the ventral mesoderm explant analyzed by histological and molecular criteria, was significantly reversed by coinjection of [Val12]Ha-Ras, c-Raf, or c-Jun mRNA. Furthermore, the BMP-4-stimulated erythroid differentiation in the ventral mesoderm was substantially inhibited by coinjection with the dominant negative c-Ha-Ras, c-Raf, or c-Jun mutant. Our results suggest the involvement of Ras/Raf/AP-1 in the BMP-4 signaling pathway.

Citing Articles

The role of heterodimeric AP-1 protein comprised of JunD and c-Fos proteins in hematopoiesis.

Lee S, Yoon J, Lee M, Jung S, Kim D, Bode A J Biol Chem. 2012; 287(37):31342-8.

PMID: 22822070 PMC: 3438963. DOI: 10.1074/jbc.M112.387266.


The function of heterodimeric AP-1 comprised of c-Jun and c-Fos in activin mediated Spemann organizer gene expression.

Lee S, Yoon J, Lee H, Hwang Y, Cha S, Jeong C PLoS One. 2011; 6(7):e21796.

PMID: 21829441 PMC: 3146467. DOI: 10.1371/journal.pone.0021796.


Histone XH2AX is required for Xenopus anterior neural development: critical role of threonine 16 phosphorylation.

Lee S, Lau A, Jeong C, Shim J, Kim H, Kim J J Biol Chem. 2010; 285(38):29525-34.

PMID: 20639511 PMC: 2937984. DOI: 10.1074/jbc.M110.127233.


Multiple signaling pathways converge to regulate bone-morphogenetic-protein-dependent glial gene expression.

Dore J, DeWitt J, Setty N, Donald M, Joo E, Chesarone M Dev Neurosci. 2009; 31(6):473-86.

PMID: 19325229 PMC: 3117193. DOI: 10.1159/000210187.


c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer.

Choi H, Bode A, Shim J, Lee S, Dong Z Mol Cell Biol. 2009; 29(8):2168-80.

PMID: 19204086 PMC: 2663297. DOI: 10.1128/MCB.01508-08.


References
1.
Chang E, Furth M, Scolnick E, Lowy D . Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature. 1982; 297(5866):479-83. DOI: 10.1038/297479a0. View

2.
Walters M, Martin D . Functional erythroid promoters created by interaction of the transcription factor GATA-1 with CACCC and AP-1/NFE-2 elements. Proc Natl Acad Sci U S A. 1992; 89(21):10444-8. PMC: 50355. DOI: 10.1073/pnas.89.21.10444. View

3.
Wozney J, Rosen V, Celeste A, Mitsock L, Whitters M, Kriz R . Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242(4885):1528-34. DOI: 10.1126/science.3201241. View

4.
Bernstein L, Colburn N . AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science. 1989; 244(4904):566-9. DOI: 10.1126/science.2541502. View

5.
Li L, Hu J, Olson E . Different members of the jun proto-oncogene family exhibit distinct patterns of expression in response to type beta transforming growth factor. J Biol Chem. 1990; 265(3):1556-62. View